Micro Digital Co., Ltd.
KOSDAQ-listed bioprocess and biomedical company supplying the CELBIC single-use cell culture system and the DxBIC automated analysis system.
As of 2026-10-11, Micro Digital Co., Ltd. has 30 Korean MFDS device approvals on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2002 and listed on KOSDAQ in 2019, Micro Digital is a total-solution supplier specializing in bioprocess and biomedical products. In its bioprocess segment it supplies the CELBIC single-use cell culture system, 3D Culture Bag, and THEBAG; in its biomedical segment it supplies the DxBIC, Nabi, Mobi, Lubi, Lumi, iSBS, and Ubi Series automated analysis systems. In 2025 revenue was KRW 12.8 billion, up 11.4% year-over-year, comprising biomedical KRW 6.03 billion (47.0%), bioprocess KRW 3.11 billion (31.1%), and other products/consumables KRW 2.82 billion (21.9%), with domestic sales of KRW 9.47 billion (73.7%) and exports of KRW 3.38 billion (26.3%), sold through about 60 partner companies across roughly 30 countries.
Products & technology
- CELBICSingle-use cell culture system for biopharmaceutical manufacturing
- 3D Culture BagSingle-use bag consumable for cell culture process
- THEBAGSingle-use bag consumable for cell culture process
- DxBIC / Nabi / Mobi / Lubi / Lumi / iSBS / Ubi SeriesAutomated absorbance/luminescence/fluorescence analysis systems for sample collection, dilution, mixing, and dispensing
Regulatory approvals
data.go.kr30 Korean MFDS device approvals · 2013–2026
- MFDSSpectrophotometer for clinical use2026-07-31Product approval · Class 1체외 제신 26-951 호
- MFDSImmunoabsorbance analyzer2025-06-02Product approval · Class 1체외 제신 25-700 호
- MFDSReal-time gene amplificator, nucleic acid2025-04-01Product approval · Class 2체외 제인 25-4262 호
- MFDSChemiluminescence assay(CLIA) analyzer2024-07-11Product approval · Class 1체외 제신 24-875 호
- MFDSChemiluminescence assay(CLIA) analyzer2024-05-07Product approval · Class 1체외 제신 24-547 호
- MFDSExtractor, nucleic acid2023-12-14Product approval · Class 1체외 제신 23-1773 호
- MFDSExtractor, nucleic acid2023-12-12Product approval · Class 1체외 제신 23-1761 호
- MFDSIVD reagents for cardiac marker2023-06-20Product approval · Class 3체외 제허 23-685 호
- MFDSIVD reagents for cardiac marker2023-05-16Product approval · Class 3체외 제허 23-583 호
- MFDSIVD reagents for cardiac marker2023-04-21Product approval · Class 3체외 제허 23-521 호
- MFDSIVD reagents for cardiac marker2023-03-10Product approval · Class 3체외 제허 23-305 호
- MFDSIVD Reagents for pregnancy/childbirth hormone and protein tests2023-03-07Product approval · Class 2체외 제인 23-4309 호
Show 18 more
- MFDSIVD reagents for cardiac marker2022-09-13Product approval · Class 3체외 제허 22-610 호
- MFDSIVD Reagents for thyroid function hormone tests2022-06-17Product approval · Class 2체외 제인 22-4456 호
- MFDSIVD reagents for tumor marker2022-03-02Product approval · Class 3체외 제허 22-140 호
- MFDSIVD reagents for cardiac marker2022-02-07Product approval · Class 3체외 제허 22-76 호
- MFDSIVD Reagents for pregnancy/childbirth hormone and protein tests2022-02-03Product approval · Class 2체외 제인 22-4070 호
- MFDSIVD reagents for tumor marker2022-01-24Product approval · Class 3체외 제허 22-47 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-12-28Product approval · Class 3체외 제허 21-1045 호
- MFDSIVD reagents for tumor marker2021-12-28Product approval · Class 3체외 제허 21-1042 호
- MFDSImmunoabsorbance analyzer2021-08-04Product approval · Class 1체외 제신 21-1067 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-04-20Product approval · Class 3체외 제허 21-307 호
- MFDSImmunoabsorbance analyzer2020-09-07Product approval · Class 1체외 제신 20-1361 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-09-02Product approval · Class 3체외 제허 20-773 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-08-19Product approval · Class 3체외 제허 20-678 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-06-25Product approval · Class 3체외 제허 20-511 호
- MFDSChemiluminescence assay(CLIA) analyzer2019-04-18Product approval · Class 1체외 제신 19-492 호
- MFDSSpectrophotometer for clinical use2017-11-09Product approval · Class 1체외 제신 17-1292 호
- MFDSImmunoabsorbance analyzer2015-11-05Product approval · Class 1체외 제신 15-349 호
- MFDSCombination stimulator, class 2Revoked2013-09-24Product approval · Class 2체외 제허 13-1635 호
Key disclosures
KRX KIND via OpenDARTShow 2 more events
Patents
KIPRIS · applicant-matchedPCT · Published · 2025-12 · Application PCT/KR2025/020956
Published · 2025-12 · Application 1020250188514
Published · 2024-12 · Application 1020240201412
Published · 2024-05 · Application 1020240068763
PCT · Published · 2024-05 · Application PCT/KR2024/095836
US · Registered · 2023-11 · Application 19099989
PCT · Published · 2023-11 · Application PCT/KR2023/017360
PCT · Published · 2023-11 · Application PCT/KR2023/017357
Registered · 2023-09 · Application 1020230119220
Registered · 2023-05 · Application 1020230067871
Show 74 more patents
US · Registered · 2023-05 · Application 18200795
US · Published · 2023-05 · Application 18872426
PCT · Published · 2023-05 · Application PCT/KR2023/006704
Registered · 2023-01 · Application 1020230002808
Registered · 2022-11 · Application 1020220150846
PCT · Published · 2022-08 · Application PCT/KR2022/012585
US · Published · 2022-07 · Application 18573620
US · Published · 2022-07 · Application 18579175
EP · Published · 2022-07 · Application 22895774.2
PCT · Published · 2022-07 · Application PCT/KR2022/009509
PCT · Published · 2022-07 · Application PCT/KR2022/009504
PCT · Published · 2022-07 · Application PCT/KR2022/009491
US · Registered · 2022-06 · Application 17854303
Rejected · 2022-03 · Application 1020220037198
Withdrawn · 2022-02 · Application 1020220025442
Registered · 2021-11 · Application 1020210159740
Registered · 2021-11 · Application 1020210154745
US · Published · 2021-10 · Application 18033784
PCT · Published · 2021-10 · Application PCT/KR2021/013777
Registered · 2021-07 · Application 1020210093378
Registered · 2021-07 · Application 1020210091522
Rejected · 2021-02 · Application 1020210023557
Rejected · 2020-11 · Application 1020200158194
Registered · 2020-11 · Application 1020200158192
Registered · 2020-11 · Application 1020200158193
Registered · 2020-11 · Application 1020200149536
CN · Published · 2020-09 · Application 202080054784.X
US · Registered · 2020-09 · Application 17765138
EP · Registered · 2020-09 · Application 20883066.1
PCT · Published · 2020-09 · Application PCT/KR2020/012959
US · Registered · 2020-03 · Application 17601954
PCT · Published · 2020-03 · Application PCT/KR2020/003762
Registered · 2019-10 · Application 1020190135116
Registered · 2019-04 · Application 1020190043900
US · Published · 2019-02 · Application 16970973
EP · Published · 2019-02 · Application 19754262.4
PCT · Published · 2019-02 · Application PCT/KR2019/001870
Rejected · 2018-12 · Application 1020180160586
Registered · 2018-02 · Application 1020180019249
Registered · 2017-12 · Application 1020170163903
Registered · 2016-11 · Application 1020160144346
Registered · 2016-10 · Application 1020160130035
Registered · 2016-04 · Application 1020160049032
PCT · Published · 2016-04 · Application PCT/KR2016/004164
Rejected · 2015-05 · Application 1020150075647
PCT · Published · 2014-07 · Application PCT/KR2014/006535
Withdrawn · 2014-04 · Application 1020140052129
Registered · 2014-04 · Application 1020140042975
PCT · Published · 2014-04 · Application PCT/KR2014/002871
Registered · 2013-08 · Application 1020130104267
Rejected · 2013-06 · Application 1020130074185
Registered · 2013-05 · Application 1020130054288
Registered · 2013-05 · Application 1020130054289
PCT · Published · 2013-04 · Application PCT/KR2013/003766
PCT · Published · 2013-04 · Application PCT/KR2013/003666
Registered · 2012-10 · Application 1020120119908
Registered · 2012-07 · Application 1020120081848
Registered · 2012-07 · Application 1020120077350
Registered · 2012-04 · Application 1020120045848
Registered · 2011-01 · Application 1020110007320
Registered · 2010-07 · Application 1020100067479
Registered · 2010-05 · Application 1020100051460
Registered · 2010-05 · Application 1020100046947
Registered · 2010-05 · Application 1020100041441
Registered · 2010-05 · Application 1020100041443
Registered · 2010-01 · Application 1020100004487
Registered · 2010-01 · Application 1020100004485
Registered · 2010-01 · Application 1020100004488
Rejected · 2008-07 · Application 1020080068682
Registered · 2007-08 · Application 1020070079669
Expired · 2006-04 · Application 1020060034625
Withdrawn · 2005-11 · Application 1020050105182
Rejected · 2004-05 · Application 1020040037626
Expired · 2004-05 · Application 1020040037614
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot48
- GoogleGoogleOther6
- PerplexityPerplexityBot4
- AnthropicClaudeBot2
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Micro Digital Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition